Heparin And Hyperkalemia Jun 2026

Heparin-induced hyperkalemia is an under-recognized but clinically significant electrolyte disorder where the administration of heparin—either unfractionated (UFH) or low-molecular-weight (LMWH)—leads to an elevation of serum potassium levels. While common side effects like bleeding or heparin-induced thrombocytopenia (HIT) are widely known, the impact on potassium homeostasis occurs in approximately 7% to 9% of patients . Mechanism of Action: The Adrenal Link The primary cause of this condition is hypoaldosteronism , where heparin inhibits the production of aldosterone in the adrenal glands. This occurs through several specific pathways: National Institutes of Health (.gov)https://pmc.ncbi.nlm.nih.gov Heparin‐induced hyperkalemia, can LMWH cause ... - PMC

Title: Heparin-Induced Hyperkalemia: Mechanisms, Risk Factors, and Clinical Implications Abstract Heparin is a widely utilized anticoagulant in both prophylactic and therapeutic settings. While its hematologic side effect, heparin-induced thrombocytopenia (HIT), is well-documented, its potential to induce hyperkalemia remains an under-recognized clinical phenomenon. Heparin inhibits the biosynthesis of aldosterone, the primary mineralocorticoid responsible for potassium homeostasis. This inhibition can lead to a state of secondary hypoaldosteronism, resulting in reduced renal potassium excretion and subsequent hyperkalemia. This paper reviews the pathophysiology of heparin-induced hyperkalemia, distinguishes between the risks associated with unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), and outlines the clinical management strategies for at-risk patients.

1. Introduction Heparin is a cornerstone of modern anticoagulation therapy, used extensively for the prevention and treatment of venous thromboembolism, as well as in the management of acute coronary syndromes. Common adverse effects include bleeding, osteoporosis with long-term use, and heparin-induced thrombocytopenia. However, electrolyte disturbances, specifically hyperkalemia, represent a less frequently discussed but potentially life-threatening complication. First reported in the literature in the 1970s, heparin-induced hyperkalemia is often overlooked in clinical practice, potentially leading to cardiac arrhythmias and increased mortality, particularly in patients with underlying renal impairment. Understanding the mechanism of aldosterone suppression is critical for preventing this iatrogenic complication. 2. Pathophysiology: The Aldosterone Connection The primary mechanism by which heparin induces hyperkalemia is through the inhibition of aldosterone synthesis. 2.1 Inhibition of Aldosterone Synthase Aldosterone is synthesized in the zona glomerulosa of the adrenal cortex. Its production is regulated by the renin-angiotensin-aldosterone system (RAAS) and potassium levels. Heparin interferes with the enzymatic pathway of steroidogenesis. Specifically, it acts as a potent inhibitor of the enzyme 18-hydroxylase (aldosterone synthase) . This enzyme is responsible for the final conversion steps of corticosterone to aldosterone. By inhibiting this enzyme, heparin reduces the production of aldosterone without significantly affecting cortisol or androgen synthesis. 2.2 Reduced Angiotensin II Receptor Expression In addition to direct enzymatic inhibition, heparin has been shown to decrease the number and affinity of angiotensin II receptors on zona glomerulosa cells. Angiotensin II is a primary stimulant for aldosterone secretion. By downregulating these receptors, heparin renders the adrenal gland less responsive to physiological stimuli that would normally trigger aldosterone release in response to hyperkalemia or hypovolemia. 2.3 Subsequent Hyperkalemia Aldosterone acts on the distal tubules and collecting ducts of the nephron to promote sodium reabsorption and potassium excretion. In the setting of heparin-induced hypoaldosteronism, the kidneys lose their capacity to effectively excrete potassium. This results in a gradual accumulation of serum potassium, leading to hyperkalemia. The effect is often termed "selective hypoaldosteronism" because the glucocorticoid axis (cortisol production) remains intact. 3. Comparative Risks: UFH vs. LMWH The risk and severity of hyperkalemia vary depending on the formulation of heparin used.

Unfractionated Heparin (UFH): UFH carries a higher risk of inducing hyperkalemia. It possesses a strong affinity for the enzymes involved in steroidogenesis. Studies have demonstrated that UFH can reduce plasma aldosterone levels by 50% or more within a few days of initiation. The effect is dose-dependent and generally reversible upon discontinuation. Low-Molecular-Weight Heparin (LMWH): Agents such as enoxaparin and dalteparin are associated with a lower incidence of hyperkalemia compared to UFH. While LMWHs still retain some capacity to inhibit aldosterone synthesis, the effect is significantly attenuated. This reduced toxicity is attributed to the purification processes and lower molecular weight, which results in less interaction with adrenal enzymes. However, in high-risk patients (e.g., those with severe renal failure), LMWH can still precipitate significant hyperkalemia. heparin and hyperkalemia

4. Risk Factors While heparin-induced aldosterone suppression can occur in healthy individuals, resulting in only mild, transient hyperkalemia, clinical significance typically arises in patients with compounding risk factors:

Renal Insufficiency: Patients with chronic kidney disease (CKD) rely heavily on aldosterone-mediated potassium excretion. When this pathway is blocked by heparin, the kidneys cannot compensate, leading to severe hyperkalemia. Diabetes Mellitus: Diabetic patients often have hyporeninemic hypoaldosteronism due to microvascular damage to the juxtaglomerular apparatus. Heparin exacerbates this pre-existing deficiency. Concurrent Medications: The use of drugs that interfere with potassium excretion significantly increases risk. These include:

ACE inhibitors and Angiotensin Receptor Blockers (ARBs). Potassium-sparing diuretics (spironolactone, eplerenone). NSAIDs and Trimethoprim. widened QRS complexes).

Duration of Therapy: The effect is time-dependent. Patients receiving prolonged heparin courses (beyond 3–5 days) are at higher risk.

5. Clinical Presentation and Diagnosis The condition is often asymptomatic until serum potassium levels reach critical thresholds. Symptoms may include:

Muscle weakness and fatigue. Palpitations. Electrocardiogram (ECG) changes (peaked T-waves, widened QRS complexes). Potassium-sparing diuretics (spironolactone

Diagnosis requires a high index of suspicion. A temporal relationship between heparin initiation and rising serum potassium is the primary clue. Laboratory confirmation may show:

Elevated serum potassium. Low or inappropriately normal plasma aldosterone levels. Low urinary potassium excretion.